Pseudomonas aeruginosa often presents as a multi-drug resistant gram-negative opportunistic pathogen responsible for chronic lung colonisation in cystic fibrosis patients and many other acute infections (Qin et al, 2022). There is an urgent need for new drug therapies against new molecular targets in this organism. This project will focus on a heretofore unexploited target in the pathogen, namely the enzyme transglutaminase (Uruburu et al, 2019), which is responsible for protein crosslinking, and without which the organism is unviable.
In preparation, at Aston, several potential inhibitors of the enzyme have been identified by means of protein-ligand molecular dynamics simulations. The project will continue with such simulations to enlarge the pool of potential inhibitors. These will be prepared by chemical synthesis and screened for inhibition of recombinantly-expressed and purified Pseudomonas transglutaminase, and if successful, for the ability to inhibit planktonic and biofilm growth of the organism. The biological test results will inform successive rounds of inhibitor optimisation. Fluorescent inhibitors will also be included with a view to probing the localisation of the inhibitor within the organism and, concomitantly, the cellular localisation of the active transglutaminase, which is postulated to be periplasmic.
References
- Uruburu et al, Journal of Structural Biology, 2019, 205, 18-25 (https://doi.org/10.1016/j.jsb.2018.12.004)
Qin et al, Sig Transduct Target Ther, 2022, 7, 199 (https://doi.org/10.1038/s41392-022-01056-1